On cancer cells from various origins, it has been shown that DCA, a PDK inhibitor currently studied in clinical trials, decreased HIF-1 activity, resulting in a reduced expression of HIF-1α target genes including pro-angiogenic factors [11,12] and a decreased tumor angiogenesis [12,13,14,15,16]. The gene discussed is HIF1A; the disease is neoplasm.